1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxylic acid | 909091-78-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxylic acid
• 英文别名: 2,4-dihydrochromeno[4,3-c]pyrazole-3-carboxylic acid
• CAS: 909091-78-7
• 化学式: C₁₁H₈N₂O₃
• mdl: MFCD03834498
• 分子量: 216.196
• InChiKey: LCCZBCRICIYZCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  75.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxylic acid 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 二氯甲烷 为溶剂， 反应 0.08h， 以25%的产率得到8-bromo-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxylic acid
  参考文献：
  名称：

  Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis

  摘要：

  Farnesoid X receptor (FXR) agonists are emerging as important potential therapeutics for the treatment of nonalcoholic steatohepatitis (NASH) patients, as they exert positive effects on multiple aspects of the disease. FXR agonists reduce lipid accumulation in the liver, hepatocellular inflammation, hepatic injury, and fibrosis. While there are currently no approved therapies for NASH, the bile acid-derived FXR agonist obeticholic acid (OCA; 6-ethyl chenodeoxycholic acid) has shown promise in clinical studies. Previously, we described the discovery of tropifexor (LJN452), the most potent non-bile acid FXR agonist currently in clinical investigation. Here, we report the discovery of a novel chemical series of non-bile acid FXR agonists based on a tricyclic dihydrochromenopyrazole core from which emerged nidufexor (LMB763), a compound with partial FXR agonistic activity in vitro and FXR-dependent gene modulation in vivo. Nidufexor has advanced to Phase 2 human clinical trials in patients with NASH and diabetic nephropathy.

  DOI：

  10.1021/acs.jmedchem.9b01621
• 作为产物：
  描述：

  ethyl 2-oxo-2-(4-oxochroman-3-yl)acetate 在 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 20.0h， 生成 1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxylic acid
  参考文献：
  名称：

  Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis

  摘要：

  Farnesoid X receptor (FXR) agonists are emerging as important potential therapeutics for the treatment of nonalcoholic steatohepatitis (NASH) patients, as they exert positive effects on multiple aspects of the disease. FXR agonists reduce lipid accumulation in the liver, hepatocellular inflammation, hepatic injury, and fibrosis. While there are currently no approved therapies for NASH, the bile acid-derived FXR agonist obeticholic acid (OCA; 6-ethyl chenodeoxycholic acid) has shown promise in clinical studies. Previously, we described the discovery of tropifexor (LJN452), the most potent non-bile acid FXR agonist currently in clinical investigation. Here, we report the discovery of a novel chemical series of non-bile acid FXR agonists based on a tricyclic dihydrochromenopyrazole core from which emerged nidufexor (LMB763), a compound with partial FXR agonistic activity in vitro and FXR-dependent gene modulation in vivo. Nidufexor has advanced to Phase 2 human clinical trials in patients with NASH and diabetic nephropathy.

  DOI：

  10.1021/acs.jmedchem.9b01621

文献信息

• [EN] TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS<br/>[FR] COMPOSÉS TRICYCLIQUES COMME MODULATEURS DES RÉCEPTEURS DE GLUTAMATES
  申请人：GLAXO GROUP LTD

  公开号：WO2010049366A1

  公开（公告）日：2010-05-06

  Disclosed herein are compounds that may be negative allosteric modulators of metabotropic receptors-subtype 5, and methods of making and using same.

  本文披露的是可能是代谢型受体亚型5的负性别构调节剂的化合物，以及制备和使用这些化合物的方法。
• TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS
  申请人：Bertinato Peter

  公开号：US20110263588A1

  公开（公告）日：2011-10-27

  The present invention relates to compounds that may be negative allosteric modulators of metabotropic receptors-subtype 5, and methods of making and using same.

  本发明涉及可能是代谢型受体亚型5的负向变构调节剂的化合物，以及制备和使用它们的方法。
• (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease
  申请人：Herbert Brian

  公开号：US20100298306A1

  公开（公告）日：2010-11-25

  The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds, which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof. The novel compounds include compounds of formula I: wherein X, R 1 , and R 2 are as herein defined.

  本发明一般涉及尼古丁乙酰胆碱受体（nACh受体）配体领域，nACh受体的激活以及与缺陷或功能障碍的尼古丁乙酰胆碱受体相关的疾病状况的治疗，特别是大脑的疾病状况。此外，本发明涉及新型化合物，其作为α7 nACh受体亚型的配体，制备这种化合物的方法，含有这种化合物的组合物以及其使用方法。这些新型化合物包括I式化合物，其中X，R1和R2的定义如本文所述。
• Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
  申请人：Burnham Institute for Medical Research

  公开号：EP2433496A1

  公开（公告）日：2012-03-28

  Disclosed herein are compounds that are tissue-nonspecific alkaline phosphatase inhibitors. The disclosed compounds are used to treat, prevent, or abate vascular calcification, arterial calcification and other cardiovascular diseases.

  本文公开的化合物是组织非特异性碱性磷酸酶抑制剂。所公开的化合物可用于治疗、预防或减轻血管钙化、动脉钙化和其他心血管疾病。
• TRICYCLIC 3-OXO-PROPANENITRILE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
  申请人：FARMITALIA CARLO ERBA S.r.l.

  公开号：EP0420883B1

  公开（公告）日：1993-11-03